People · Operator
Named in public records as an officer, director or promoter · active 2010–2019 · Biotechnology, Manufacturing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cidara Therapeutics, Inc. | — | Biotechnology | Series D+ | $349.1M | $2.8B | 2017 |
| Perfinity Biosciences, Inc. | — | Manufacturing | Seed | $4.7M | $28.6M | 2010 |
Timothy R. Franson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Timothy R. Franson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Nina Kjellson | 1 | 11 |
| Patrick Heron | 1 | 11 |
| SCOTT ROCKLAGE | 1 | 9 |
| R. Matthew Neff | 1 | 5 |
| Steve Elms | 1 | 4 |
| Scott M. Rocklage | 1 | 4 |
| Jeffrey Stein | 1 | 4 |
| Theodore R. Schroeder | 1 | 4 |
| Daniel D. Burgess | 1 | 3 |
| Kevin Forrest | 1 | 3 |
| Dirk Thye | 1 | 3 |
| Kevin Judice | 1 | 3 |
| Michael A. Evans | 1 | 2 |
| Ted Schroeder | 1 | 1 |
| Drew F. Peyronnin | 1 | 1 |
| Ken Bartizal | 1 | 1 |
| Fred F. Regnier | 1 | 1 |
| Dan Burgess | 1 | 1 |
| Steven Plump | 1 | 1 |
| Frank P. Cheng | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.